Helix Biopharma Corp Stock Price To Earnings To Growth
| HBP Stock | CAD 0.87 0.07 7.45% |
Helix BioPharma Corp fundamentals help investors to digest information that contributes to Helix BioPharma's financial success or failures. It also enables traders to predict the movement of Helix Stock. The fundamental analysis module provides a way to measure Helix BioPharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Helix BioPharma stock.
Helix | Price To Earnings To Growth |
Helix BioPharma Corp Company Price To Earnings To Growth Analysis
Helix BioPharma's PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Helix Price To Earnings To Growth Driver Correlations
Understanding the fundamental principles of building solid financial models for Helix BioPharma is extremely important. It helps to project a fair market value of Helix Stock properly, considering its historical fundamentals such as Price To Earnings To Growth. Since Helix BioPharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Helix BioPharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Helix BioPharma's interrelated accounts and indicators.
Click cells to compare fundamentals
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
| Competition |
Helix Price Earnings To Growth Ratio
Price Earnings To Growth Ratio |
|
Based on the latest financial disclosure, Helix BioPharma Corp has a Price To Earnings To Growth of 0.0 times. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The price to earnings to growth for all Canada stocks is 100.0% higher than that of the company.
Helix BioPharma Current Valuation Drivers
We derive many important indicators used in calculating different scores of Helix BioPharma from analyzing Helix BioPharma's financial statements. These drivers represent accounts that assess Helix BioPharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Helix BioPharma's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 59.7M | 69.0M | 114.4M | 40.6M | 51.2M | 97.2M | |
| Enterprise Value | 59.5M | 64.9M | 114.5M | 39.8M | 50.1M | 91.4M |
Helix Fundamentals
| Return On Equity | -22.21 | ||||
| Return On Asset | -4.59 | ||||
| Current Valuation | 41.57 M | ||||
| Shares Outstanding | 49.02 M | ||||
| Shares Owned By Insiders | 2.15 % | ||||
| Number Of Shares Shorted | 2.6 K | ||||
| Price To Earning | (7.09) X | ||||
| Price To Book | 77.46 X | ||||
| EBITDA | (9.38 M) | ||||
| Net Income | (9.26 M) | ||||
| Cash And Equivalents | 938 K | ||||
| Cash Per Share | 0.01 X | ||||
| Total Debt | 1.58 M | ||||
| Current Ratio | 0.37 X | ||||
| Book Value Per Share | (0) X | ||||
| Cash Flow From Operations | (5.22 M) | ||||
| Short Ratio | 0.15 X | ||||
| Earnings Per Share | (1.05) X | ||||
| Target Price | 2.5 | ||||
| Beta | -0.84 | ||||
| Market Capitalization | 42.65 M | ||||
| Total Asset | 1.49 M | ||||
| Retained Earnings | (210.67 M) | ||||
| Working Capital | (123 K) | ||||
| Net Asset | 1.49 M |
About Helix BioPharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Helix BioPharma Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Helix BioPharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Helix BioPharma Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Helix BioPharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Helix BioPharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Helix BioPharma will appreciate offsetting losses from the drop in the long position's value.Moving against Helix Stock
| 0.79 | RY-PM | Royal Bank | PairCorr |
| 0.74 | RY-PS | Royal Bank | PairCorr |
| 0.73 | TD-PFI | Toronto Dominion Bank | PairCorr |
| 0.67 | BNS | Bank of Nova Scotia | PairCorr |
| 0.67 | TD-PFD | Toronto Dominion Bank | PairCorr |
The ability to find closely correlated positions to Helix BioPharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Helix BioPharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Helix BioPharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Helix BioPharma Corp to buy it.
The correlation of Helix BioPharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Helix BioPharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Helix BioPharma Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Helix BioPharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Helix Stock
Helix BioPharma financial ratios help investors to determine whether Helix Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Helix with respect to the benefits of owning Helix BioPharma security.